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Divalent metal transporter-1 (DMT1) mediates dietary iron uptake across the intestinal
mucosa and facilitates peripheral delivery of iron released by transferrin in the endosome.
Here, we report that classical cannabinoids (Δ9-tetrahydrocannabinol, Δ9-THC), nonclassi-
cal cannabinoids (CP 55,940), aminoalkylindoles (WIN 55,212-2) and endocannabinoids
(anandamide) reduce 55Fe and 54Mn uptake by HEK293T(DMT1) cells stably expressing
the transporter. siRNA knockdown of cannabinoid receptor type 2 (CB2) abrogated inhib-
ition. CB2 is a G-protein (GTP-binding protein)-coupled receptor that negatively regulates
signal transduction cascades involving serine/threonine kinases. Immunoprecipitation
experiments showed that DMT1 is serine-phosphorylated under basal conditions, but
that treatment with Δ9-THC reduced phosphorylation. Site-directed mutation of predicted
DMT1 phosphosites further showed that substitution of serine with alanine at N-terminal
position 43 (S43A) abolished basal phosphorylation. Concordantly, both the rate and
extent of 55Fe uptake in cells expressing DMT1(S43A) was reduced compared with those
expressing wild-type DMT1. Among kinase inhibitors that affected DMT1-mediated iron
uptake, staurosporine also reduced DMT1 phosphorylation conﬁrming a role for serine
phosphorylation in iron transport regulation. These combined data indicate that phos-
phorylation at serine 43 of DMT1 promotes transport activity, whereas dephosphorylation
is associated with loss of iron uptake. Since anti-inﬂammatory actions mediated through
CB2 would be associated with reduced DMT1 phosphorylation, we postulate that this
pathway provides a means to reduce oxidative stress by limiting iron uptake.
Introduction
Divalent Metal Transporter-1 (DMT1; Slc11A2) mediates ferrous (Fe2+) iron uptake across the small
intestine [1] and the delivery of iron to peripheral tissues by transferrin [2]. Electrophysiological
studies have shown that DMT1 not only transports Fe2+, but that it also interacts with other divalent
metals [3]. DMT1 activity is voltage and pH-dependent [4]. The SLC11A2 gene encoding DMT1 pro-
duces multiple isoforms through alternative promoters (1A or 1B) and/or alternative splicing to
produce transcripts with or without an iron regulatory element (+IRE or −IRE) [5]. While 1A iso-
forms are predominantly expressed in duodenum and kidney, 1B isoforms are ubiquitously expressed
[5]. The 1A isoform is regulated by hypoxia-inducible factor 2α response elements that increase intes-
tinal DMT1 expression in response to hypoxia [6,7]. Protein levels of the +IRE isoforms increase
during times of deﬁciency, and iron-dependent post-transcriptional control of IRE-containing DMT1
transcripts by iron regulatory proteins has been demonstrated [8,9]. The membrane proteins generated
by various DMT1 transcripts have different subcellular targeting. All DMT1 isoforms display similar
function and equal efﬁciency, but the 1A/+IRE isoform is predominantly detected at the plasma mem-
brane, whereas the 1A/−IRE, 1B/+IRE and 1B/−IRE isoforms are more abundant in intracellular compart-
ments [10,11]. The tissue-speciﬁc expression and subcellular localization of different DMT1 isoforms may
regulate iron transport by distinct membranes and organelles in different cell types. In addition, DMT1 is
regulated post-translationally by ubiquitination mediated through Ndﬁps (NEDD4 family-interacting
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protein 2) and WWP2 (WW domain-containing E3 ubiquitin protein ligase 2), which control its degradation
[12]. In summary, DMT1 expression and activity are highly regulated at the transcriptional, post-transcriptional
and post-translational levels. Since excess iron is associated with oxidative stress and cytotoxicity, these various
mechanisms controlling iron assimilation by DMT1 are critical to maintaining cellular homeostasis.
Small molecule inhibitors can help to further identify factors involved in the regulation of iron transport
activity. Our previous screen of bioactive molecules revealed that the cannabinoid Δ9-tetrahydrocannabinol
(Δ9-THC) inhibits DMT1 function [13]. Δ9-THC effects are mediated through cannabinoid receptors (canna-
binoid receptor type 1, CB1 and cannabinoid receptor type 2, CB2), members of the G-protein (GTP-binding
protein)-coupled receptor class [14]. The cannabinoid system has been implicated in many physiological func-
tions, both in the central and peripheral nervous system and in peripheral organs, providing a therapeutic
target for many pathological conditions [15]. In particular, the cannabinoid system has been shown to nega-
tively couple to N- and P/Q-type voltage-operated Ca2+ channels [16–18] and positively couple to A-type and
inwardly rectifying K+ channels [19,20]. Cannabinoids have also been shown to inhibit acid-sensing channels
[21] and Na+-dependent amino acid transporters [22]. We undertook this study to determine the mechanism
through which Δ9-THC inhibits DMT1-mediated iron transport, since this pathway would also provide thera-
peutic opportunities to limit assimilation to prevent iron overload diseases.
Experimental procedures
Plasmid construction
The hemagglutinin (HA)-tagged mouse DMT1 (non-IRE exon 1B isoform) plasmid [23] was generously pro-
vided by Dr Philippe Gros (McGill University). In this construct, the HA tag (YPYDVPDYA) is inserted in the
predicted extracellular domain between transmembrane domains 7 and 8 [24]. Previous work by this group has
characterized the transport activity [24,25] and membrane trafﬁcking [26,27] of this construct to demonstrate
its compatibility with properties of wild-type DMT1 (non-IRE 1B). In the present study, site-directed mutations
on this plasmid (S21A-HA, S23A-HA, S32A-HA, S39A-HA and S43A-HA) were constructed using the
QuikChange® II XL kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s protocol. The site-
directed mutation, orientation and ﬁdelity of the inserts, and incorporation of the epitope tags, were conﬁrmed
by directed sequencing (Dana Farber/Harvard Cancer Center DNA Resource Core).
Cell culture and transient transfection
HEK293T(DMT1) cells [13] were cultured in α-minimal essential medium supplemented with 50 U/ml penicil-
lin, 50 μg/ml streptomycin and 10% fetal bovine serum. To transiently express HA-tagged DMT1 (DMT1-HA),
parental HEK293T cells were transfected with 0.5 mg (24-well plates), 4 mg (6-well plates) or 24 mg (10 cm2
dishes) of wild-type or mutant alleles of DMT1 plasmid in serum- and antibiotic-free medium using
Lipofectamine 2000 (Invitrogen) at a DNA:transfection reagent ratio of 1:2.5 according to the manufacturer’s
speciﬁcations. Transfection medium was replaced 4–6 h later with antibiotic-free growth medium, and cells
were cultured for an additional 24 h prior to experiments.
Transport studies with radioisotopic tracer
HEK293T(DMT1) cells were grown to 60–80% conﬂuence in 10-cm plates, and washed three times with PBS
containing 1 mM MgCl2 and 0.1 mM CaCl2 (PBS++), and lifted by carefully pipetting up and down into PBS++
or uptake buffer (25 mM Tris, 25 mM MES, 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4
and 5 mM glucose, pH 6.75). Cell counts were determined and samples were aliquoted for studies. Δ9-THC
(Sigma), CP 55,940 (Tocris Bioscience), WIN 55,212-2 (Tocris Bioscience), anandamide (Tocris Bioscience),
staurosporine (LC Laboratories), H-7, GDPβS, Sp-8-bromo-cAMP (Sigma Chemical Co.), U0126-EtOH, trame-
tinib or PD0325902 (Selleck Chemicals) were added to cell aliquots at the indicated concentrations and com-
pared with control cell aliquots treated with the appropriate vehicle (water or 0.5% DMSO, v/v). In the
standard assay, cells were incubated at 37°C for 20 min in uptake buffer containing 1 μM 55Fe and 50 μM
ascorbic acid (pH 6.75). Cells were chilled on ice, collected on nitrocellulose ﬁlters and washed three times by
centrifugation or vacuum ﬁltration with ice-cold PBS to remove any unbound 55Fe or 54Mn. Cells were lysed
with solubilization buffer (0.1% Triton X-100/0.1% NaOH), and cell-associated radioactivity was determined by
scintillation counting. Uptake was calculated as pmol per million cells per min and was normalized to control
(vehicle alone) to determine the extent of inhibition in the presence of a drug as indicated in the legends. In
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experiments employing HEK293T cells transiently expressing DMT1 and various mutants, transport assays
were carried out for the times indicated in the ﬁgures and legends by using individual wells that were each sep-
arately transfected. In these experiments, cells from each well were lysed and uptake was measured by scintilla-
tion counting, then adjusted to lysate cell protein for that individual well measured using the Bradford assay.
Uptake is shown as pmol/mg protein.
Small interfering RNA-mediated gene suppression of cannabinoid receptor
HEK293T(DMT1) cells (1 × 105 cells per well) were plated in six-well plates overnight and then transfected with
100 nM of control siRNA (Ambion), CB1 siRNA (CNR1-s3261, Ambion) or CB2 siRNA (CNR2-s3263, Ambion)
using Lipofectamine 2000 (Invitrogen) as described above. After 24 h incubation, the transfection medium was
replaced with serum-containing, antibiotic-free medium, and cells were cultured for another 16 h before experi-
ments. Cells were collected for the determination of CB1 and CB2 protein abundance and 55Fe uptake.
Immunoblot analysis
Cells were washed twice with ice-cold PBS, and the total cell lysates were prepared in lysis buffer containing
150 mM NaCl, 1 mM EDTA, 50 mM Tris and 1% Triton containing a protease inhibitor cocktail (Complete
Mini, Roche). Protein concentration was determined by the Bradford assay. Samples (25 mg) were separated by
electrophoresis on 10% SDS–PAGE gels and transferred to PVDF membranes, and immunoblotted with rabbit
anti-CB1 or -CB2 antibody (Cayman Chemical Company). The primary antibody was detected with IRDye
800-conjugated secondary antibodies (Rockland Immunochemicals, Inc.). After further washing, immunoreac-
tivity was detected by an Odyssey Infrared Imaging System (Li-COR).
Immunoprecipitation experiments
To determine HA-DMT1 phosphorylation, cells transfected with HA-DMT1 or empty vector were scraped into
ice-cold PBS and pelleted by centrifugation, then lysed in Nonidet-P40 (NP-40) buffer (40 mM HEPES, pH 7.4,
120 mM NaCl, 5% glycerol, 1% NP-40 and 1 mM EDTA, pH 8.0) containing phosphatase inhibitors (10 mM
pyrophosphate, 10 mM β-glycerophosphate, 50 mM NaF and 0.5 mM orthovanadate) for 30 min at 4°C with
rotation. Samples were centrifuged for 10 min at 15 000×g, and the protein concentration of the lysates was deter-
mined by the Bradford assay. The cell lysates were preincubated with anti-HA agarose (Pierce) overnight at 4°C
with rotation and washed with TBS before protein elution at 95°C for 5 min. Eluates were electrophoresed on 4–
20% gradient gels, transferred to PVDF membranes and the extent of HA-DMT1 phosphorylation was assessed
by immunoblotting with mouse antiphosphoserine antibody (Millipore) followed by IRDye 800-conjugated sec-
ondary antibodies (Rockland Immunochemicals). Meanwhile, total cell lysates were immunoblotted with either
anti-HA antibody or by antiactin antibody followed by IRDye800-conjugated secondary antibodies. After further
washing, immunoreactivity was detected by an Odyssey Infrared Imaging System (Li-COR).
Statistical analysis
Statistical comparisons were determined using unpaired Student’s t-test (Prism Graph Pad, Berkeley, CA,
USA). In Figure 1, dose–response curves were best ﬁt by a Hill four-parameter sigmoidal model with analysis
made using Sigmaplot (Systat software). In Figure 2B, data were analyzed by two-way ANOVA followed by
Holm–Sidak’s multiple comparisons test for pairwise comparisons. In Figure 4C, where comparisons were
made by one-way ANOVA followed by Tukey post hoc analysis. Results shown are means ± SEM unless other-
wise indicated. For all statistical analyses, results were considered signiﬁcant at P < 0.05.
Results
Cannabinoids inhibit DMT1-mediated iron (II) uptake
Our previous study showed that Δ9-THC inhibited DMT1 activity with an IC50 of ∼0.45 μM [13]. We further
examined the effect of different types of cannabinoids on iron uptake using an 55Fe tracer assay. Inhibition of
HEK293T cells stably overexpressing DMT1 by the endogenous cannabinoid anandamide, and synthetic canna-
binoids structurally unrelated to the ‘classic cannabinoid Δ9-THC, including the so-called nonclassical canna-
binoid CP 55,940 and the aminoalkylindole agonist WIN 55,212-2, was examined (Figure 1A). The IC50 values
were all below 10 mM (see table in Figure 1). The values for y(min) determined from regression analysis
suggest an index of efﬁcacy of CP 55,940 (30.9%) > anandamide (36.1%) >WIN 55,121-2 (56.8%). These
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combined data indicate that both exogenous and endogenous cannabinoids inhibit DMT1-mediated iron
uptake in a dose-dependent manner. Since DMT1 transports other divalent metals, we also conﬁrmed the
effects of cannabinoids on 54Mn uptake, which was reduced by anandamide and CP 55,940 (Figure 1B).
CB2 mediates inhibition by Δ9-THC
Cannabinoids produce many biological effects primarily mediated through interactions with cannabinoid recep-
tors CB1 and CB2 [14]. To determine whether iron transport inhibition by Δ9-THC was due to interactions of
either cannabinoid receptor, we used siRNA to knockdown CB1 and CB2 in HEK293T(DMT1) cells. Western
blot analysis showed that CB1 and CB2 receptors were effectively reduced compared with control cells
(Figure 2A). DMT1-mediated 55Fe uptake and its response to Δ9-THC were unaffected by CB1 knockdown
(Figure 2B). Knockdown of CB2 reduced the total amount of iron taken up in the absence of Δ9-THC, at 2 μM
Δ9-THC and at 10 μM Δ9-THC in CB2 siRNA-treated cells compared with the control siRNA-treated cells
(Figure 2B). These results indicate that inhibition of iron transport is dependent on the expression of CB2.
Under basal conditions, the presence of this receptor appears to enhance DMT1 activity, supporting the idea
that cannabinoid agonists act through CB2 to suppress transporter function.
CB2 is a member of the G-protein-coupled receptor family and is known to negatively regulate adenylate
cyclase through its interactions with Gi/Go α subunits. To further delineate its potential role in the regulation
of DMT1-mediated iron transport, we studied activators and inhibitors of this signaling pathway (Figure 3).
The treatment of HEK293T(DMT1) cells with the GDP analog GDPβS reduced iron uptake. In contrast, the
Gi/o protein activator pertussis toxin enhanced transport. Likewise the cAMP agonist sp-8-Br-cAMP enhanced
iron transport, consistent with the idea that negative regulation of adenylate cyclase leads to inhibition of
DMT1 activity. H7, a cAMP-protein kinase (PKA) inhibitor, reduced iron transport by a small but reproducible
Figure 1. Dose–response studies of DMT1 inhibition by cannabinoids.
HEK293T(DMT1) cells were incubated at 37°C for 20 min with 0.001–100 μM of the indicated compounds as described in the
Experimental Procedures section (n = 6). Shown are curves ﬁt by regression analysis with symbols indicated in (A). (B) 54Mn
uptake in the absence and presence of 50 mM anandamide or CP55,940. Shown are means (±SEM) for control cells incubated
with vehicle (DMSO) and indicated drug (n = 3); results from one experiment with similar results obtained on at least one other
occasion (*P < 0.0001). Dose response curves were best ﬁt by a Hill four-parameter sigmoidal model with values obtained for
Ymax, Ymin, and IC50 shown in the inserted table. The P-values and R
2 for each of the curve ﬁts are also provided.
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extent. Staurosporine, a broad spectrum PKA and protein kinase C (PKC) inhibitor, had a greater dose-
dependent effect (see below). Through interactions with the G-protein βγ subunit, CB2 can also couple to
mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK). We, therefore, also tested
transport inhibition by the kinase inhibitors U0126-EtOH (50 μM), trametinib (5 μM) or PD0325902 (50 μM),
but did not observe any signiﬁcant or reproducible effects (data not shown).
Serine phosphorylation of DMT1 is blocked by Δ9-THC
As discussed above, CB2 receptor signal transduction mechanisms regulate serine/threonine phosphorylation
by many different kinases. To more directly examine possible phosphorylation of DMT1 and effects of
Δ9-THC, HEK293T cells were transfected to transiently express HA-tagged DMT1. These cells and control cells
(transfected with empty plasmid) were treated with or without Δ9-THC. Anti-HA antibodies were used to
immunoprecipitate HA-DMT1 from cell lysates, which was then immunoblotted to detect phosphoserine.
Antiphosphoserine antibodies were detected phosphorylation of HA-DMT1 in the absence of Δ9-THC. The
extent of DMT1 serine phosphorylation was reduced in cells treated with the cannabinoid (Figure 4A). The
results are consistent with the idea that under basal conditions, active DMT1 is serine-phosphorylated and in
response to CB2 activation, the inactivated transporter is dephosphorylated.
Two independent computer-assisted approaches that predict phosphorylation sites were used to examine
potential DMT1 target residues: PhosphoSitePlus [28] and NetPhos 2.0 server [29]. Both algorithms revealed
possible phosphosites in the N-terminal cytoplasmic domain (S21, S23, S32, S39 and S43) on DMT1 (Figure 4A).
These residues are all conserved in four known protein isoforms of DMT1. To determine if these serine resi-
dues play a role in DMT1 phosphorylation, we replaced each serine residue individually with alanine by site-
directed mutagenesis and tested HA-DMT1 phosphorylation. Our results showed that point mutation of serine
to alanine at 43 (S43A) completely abolished basal phosphorylation of DMT1 (Figure 4B).
Figure 2. Loss of CB2 receptor abrogates Δ9-THC inhibition of iron transport.
(A) A representative immunoblot of CB1 or CB2 receptor levels in cells transfected with control, CB1 or CB2 receptor-speciﬁc
siRNA. Equal loading was veriﬁed by immunoblotting with antiactin antibody. (B) Inhibition of iron uptake by CB1 or CB2
receptor-attenuated cells incubated with 2 or 10 μM of Δ9-THC. Results shown are means ± SEM from at least two independent
experiments (n = 5). *Two-way ANOVA followed by Holm–Sidak’s multiple comparisons test showed that CB2 knockdown
reduced iron transport in the absence of Δ9-THC (P = 0.0003), at 2 mM Δ9-THC (P = 0.0114) and at 10 mM Δ9-THC (P = 0.0216)
compared with controls.
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DMT1 phosphorylation at serine 43 promotes iron uptake
To conﬁrm that S43 is a phosphorylation site important for DMT1 function, cells were transfected to express
S43A-HA. Control immunoprecipitation experiments conﬁrmed that this mutant failed to be phosphorylated
when compared with serine phosphorylation of wild-type DMT1 (Figure 5). Subsequently, the transport of iron
by cells expressing the serine mutant was tested using the 55Fe tracer assay. As shown in Figure 5B,C, expression
of the S43A-HA mutant produced lower 55Fe uptake compared with cells expressing wild-type DMT1. The input
controls (Figure 5A) conﬁrm that the expression of wild-type and the S43A mutant in transfected HEK293T
cells are similar, suggesting that the change in iron uptake reﬂects altered activity of the latter. Both the rate
and extent of iron transport were reduced in cells expressing S43A-HA compared with wild-type DMT1-HA.
To test the potential role of phosphorylation in DMT1 transport function, the effects of the serine/threonine
protein kinase inhibitor staurosporine on iron uptake were determined. Staurosporine inhibited
DMT1-mediated 55Fe uptake in a dose-dependent manner (Figure 6A). To conﬁrm the inhibition of protein
Figure 3. Inhibitors and activators of DMT1-mediated iron uptake.
Results of transport assays performed as described in Figure 1 are shown for indicated agents compared with vehicle control
(0.5% DMSO, v/v, bottom panel) or water alone (top panel). Results are from single independent experiments’ means ± SEM
determined for biological triplicates with similar results obtained on at least two separate occasions. For pertussis toxin (PTX)
experiments, cells were treated with 100 ng/ml toxin added to culture medium for at least 24 h prior to assays (*P < 0.01;
**P < 0.05).
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kinase activity not only blocked Fe transport but was also associated with reduced serine phosphorylation,
HEK293T cells transiently transfected to express HA-tagged DMT1 were treated with or without staurosporine,
and anti-HA antibodies were used to immunoprecipitate HA-DMT1 from cell lysates to detect phosphoserine.
As predicted, serine phosphorylation of HA-DMT1 was reduced in cells treated with staurosporine compared
Figure 4. Serine phosphorylation of DMT1 is blocked by Δ9-THC.
(A) HEK293T cells were transiently transfected with an empty vector or DMT1-HA. Cells were preincubated with a phosphatase
inhibitor in PBS++ at 37°C for 15 min and then spun down, resuspended in uptake buffer containing a phosphatase inhibitor
with 50 μM Δ9-THC or control vehicle (0.5% DMSO, v/v) at 37°C for 20 min. After immunoprecipitation with anti-HA, samples
were immunoblotted to determine serine phosphorylation (IP: HA and IB: Phosphoserine) compared with immunoprecipitated
DMT1-HA protein (IP: HA and IB: HA). Total cell lysates from the same samples (Input) were used to detect DMT1-HA protein
(IB: HA) and actin was used as a loading control (IB: Actin). Amino acid alignment between mouse DMT1 isoforms (1B/+IRE,
1B/−IRE, 1A/+IRE and 1A/−IRE) was generated with ClustalW. The predicted phosphorylation sites are located in a conserved
region (marked with bold letters) before the ﬁrst predicted transmembrane domain (marked with a bold, gray line under amino
acid sequence). (B) HEK293 cells were transfected to express DMT1-HA and serine mutants (S21A-HA, S23A-HA, S32A-HA,
S39A-HA and S43A-HA). DMT1 was immunoprecipitated from the cell lysates with anti-HA antibody (IP: HA) and immunoblotted
with antiphosphoserine antibody (IP: HA and IB: Phosphoserine). Blots were then stripped and reprobed with anti-HA (IP: HA
and IB: HA) as a loading control. Total cell lysates from the same samples (Input) were used to detect total abundance of
DMT1-HA protein and actin.
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with vehicle-treated control cells (Figure 6B). Figure 6C shows densitometric data obtained from two independ-
ent experiments with a 50% decrease in HA-DMT1 phosphorylation in staurosporine-treated cells. It has been
shown that staurosporine induces apoptotic cell death in many different cell lines [30–32]. However, in our
experiments, we did not observe any signs of cell death over the short 20 min time course of incubation (Y.A.
S., personal observation).
Discussion
Previous studies from our research group applied chemical genetics to advance our understanding of different
pathways of iron uptake through the discovery of transport inhibitors [13,33–35]. The bioactive small molecule
Δ9-THC was identiﬁed to block iron uptake by DMT1 in HEK293T(DMT1) cells [13]. The present study
shows that the CB2 receptor is responsible for mediating the effects of Δ9-THC on DMT1 activity in this cell
line. In Δ9-THC-treated cells, serine phosphorylation of DMT1 was signiﬁcantly reduced. These observations
indicate that the transporter’s function can be regulated by limiting its phosphorylation or promoting its
dephosphorylation. Consistent with this model, site-directed mutagenesis studies revealed that conversion of
DMT1 Ser43 to Ala results in loss of phosphorylation and iron uptake activity. All of these functional effects
correlate with inhibition of uptake observed in the presence of cannabinoid agonists.
The fact that Ser43 is present in all DMT1 isoforms suggests that regulation at this site is independent of the
C-terminus of the protein; i.e. occurring in both +IRE and −IRE isoforms. Previous studies reported that
Nramp1 (natural resistance-associated macrophage protein) [36], a macrophage-speciﬁc homolog of Nramp2
or DMT1 [37], is also post-translationally modiﬁed by phosphorylation [38]. Although speciﬁc phosphorylation
site(s) have not been determined, the Nramp1 protein contains several possible PKC and casein kinase II
(CK-2) sites [38,39]. Barton et al. [39] have shown that a peptide corresponding to the N-terminal domain of
Nramp1 is phosphorylated and suggested that this modiﬁcation reﬂects PKC activity. Beyond the preliminary
identiﬁcation of Nramp1 as a phosphoprotein, little is known about functional effects of this modiﬁcation. Our
observation is the ﬁrst report of DMT1 (Nramp2) phosphorylation. Computer-based programs, such as
KinasePhos [40], GPS (group-based prediction system) [41] and PPSP (prediction of PK-speciﬁc phosphoryl-
ation site) [42], all indicate that the Ser43 in DMT1 is a potential site for protein kinase A/G/C family
members as well as CK-2. Further research is necessary to precisely deﬁne the kinase(s) involved in recognition
of the Nramp transporter family and how this post-translational modiﬁcation affects their transport mechan-
ism. It has been suggested that PKCβ could play a role in Nramp1 regulation, based on regulation of this
Figure 5. DMT1 phosphorylation at serine 43.
(A) HEK293T cells were transfected to express DMT1-HA or S43A-HA, and immunoprecipitation and immunoblot analysis were
performed as described in Figure 3. (B) Time course of iron uptake by HEK293T cells transfected to express HA-DMT1 (closed
circles) or HA-DMT1(S43A) (closed triangles) compared with mock-transfected control (empty circles) cells (n = 3). Similar
results were obtained in at least two independent experiments. *P < 0.05 vs. control; #P < 0.05 vs. S43A. SEM values are
provided since errors bars are too small to visualize. (C) The extent of iron uptake over a 20-min incubation period was
determined for HEK293T cells transfected to express DMT1-HA (ﬁlled bar), S43A-HA (gray bar) or mock-transfected (open bar).
Results shown are means ± SEM (n = 3) with similar results obtained in at least two independent experiments (n = 3). Means
with different letters are signiﬁcantly different by one-way ANOVA followed by Tukey’s multiple comparisons test (P < 0.0001).
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kinase by iron [43]. We have found that staurosporine, a broad spectrum inhibitor of both protein kinases
PKA and PKC [44], reduces both DMT1 transport activity and phosphorylation, but further study is necessary
to identify the DMT1 serine kinase and its relationship to other Nramp family kinases.
Although the C-termini of DMT1 isoforms have been shown to direct subcellular trafﬁcking [27], the possi-
bility that phosphorylation of the N-terminal Ser43 redirects subcellular localization of DMT1 to modulate its
function must be considered [45]. It is interesting to note that the peripheral benzodiazepine receptor-
associated protein 7 (PAP7) has been implicated in DMT1 trafﬁcking [46]. This factor is functionally linked
with the G-protein-coupled benzodiazepine receptor and associates with a cAMP-dependent kinase [47]. In a
similar fashion, CB2 might regulate phosphorylation or dephosphorylation of DMT1 through a third partner
akin to PAP7. We have attempted to study changes in DMT1 cellular localization upon cannabinoid treatment,
as well as in response to kinase inhibitors, but failed to observe major redistribution of transporters in
HEK293T(DMT1) cells or in HEK cells transiently overexpressing the HA-tagged DMT1. Both ﬂuorescence
confocal microscopy and cell surface biotinylation did detect surface transporters (data not shown) as previ-
ously demonstrated [17]. Further work is necessary to determine how phosphorylation of DMT1’s N-terminus
may affect iron transport. It has been shown that the copper transporter ATP7B is basally phosphorylated and
becomes hyperphosphorylated in response to increased copper levels and although the functional consequences
have yet to be fully determined, this activity does not affect membrane trafﬁcking [48].
Figure 6. Staurosporine inhibits DMT1 transport and reduces serine phosphorylation.
(A) Iron uptake by HEK293T(DMT1) cells was assayed after incubation with indicated concentrations of staurosporine in
phosphate-buffered saline with glucose (PBSG)++ at 37°C for 20 min. The histogram represents three experiments done in
triplicate and results shown are mean values ± SEM for inhibition, *P < 0.001. (B) Serine phosphorylation of DMT1 was
determined by immunoprecipitation as described in Figure 3, except after a preincubation step with a phosphatase inhibitor in
PBS++ at 37°C for 15 min, followed by assays containing a phosphatase inhibitor with 20 μM staurosporine or vehicle (0.5%
DMSO, v/v) at 37°C for 20 min. Immunoprecipitation was performed using an anti-HA antibody (IP: HA) and immunoblotting
was performed (IP: HA and IB: Phosphoserine) in comparison with immunoprecipitated DMT1-HA protein (IP: HA and IB: HA).
Total cell lysates from the same samples (Input) were used to detect DMT1-HA protein (IB: HA) and actin was used as a
loading control (IB: Actin). (C) Mean ratio of DMT1-HA: Actin ± SD from untreated cells (−) and cells treated with staurosporine
(+) determined by densitometry of two independent experiments as described in B.
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To our knowledge, the demonstration that CB2 modulates iron uptake activity is also the ﬁrst report of
endocrine receptor regulation of DMT1 transport. A growing body of evidence has shown the expression of
CB2 receptors in microglial cells, astrocytes and some neuron populations [49]. The function of CB2 in micro-
glia, the macrophages of the brain, is of particular interest since receptor activation decreases the in vitro pro-
duction of proinﬂammatory molecules in rat [50,51] and human [52] microglial cells. CB2 activation also
reduces the release of proinﬂammatory factors in a model of hypoxic–ischemic brain damage in newborn rats
[53] and in Huntington’s disease [54]. Moreover, recent evidence shows that microglia express a functional
endocannabinoid signaling system and that CB2 receptors control their immune-related functions [55]. Iron is
also an important regulator of immune cell function [56], and CB2 regulation of DMT1 iron uptake activity
could potentially reﬂect an important physiological response associated with iron withdrawal during anti-
inﬂammatory responses [57]. Our work in an immortalized microglial cell line has recently demonstrated that
the CB2 selective agonist JWH-015 markedly reduces inﬂammation promoted by the Alzheimer’s disease
protein amyloid-β [58]. A decrease in iron import would be consistent with this effect. While there are many
studies on iron regulation and its effects on peripheral macrophages and immune function, very little is known
regarding microglial iron handling [59]. Thus, it will be interesting to test whether microglia utilize the canna-
binoid signaling system to modulate cellular iron status through the regulation of DMT1 function.
Further studies are also warranted to determine the detailed mechanism through which DMT1 phosphoryl-
ation is responsible for controlling its activity. DMT1 is regulated at transcriptional [6,60], post-transcriptional
[8,9] and post-translational levels [61]. Our study demonstrates that phosphorylation at S43 is linked to a func-
tionally active state of the transporter’s function. Understanding how DMT1 function is modiﬁed by this post-
translational modiﬁcation may provide insights about the membrane transport of iron. Moreover, since Ser43
phosphorylation activates DMT1 under basal conditions, dephosphorylation at this site provides an interesting
potential target for pharmacological tools to treat diseases of iron overload.
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